Format

Send to

Choose Destination
Am J Clin Exp Urol. 2013 Dec 25;1(1):18-24. eCollection 2013.

Splicing variants of androgen receptor in prostate cancer.

Author information

1
Department of Pathology and Laboratory Medicine, Tulane University School of Medicine New Orleans, LA ; Department of Tulane Cancer Center New Orleans, LA.
2
Department of Structural and Cellular Biology, Tulane University School of Medicine New Orleans, LA.
3
Department of Pathology and Laboratory Medicine, Tulane University School of Medicine New Orleans, LA.
4
Department of Urology, Tulane University School of Medicine New Orleans, LA ; Department of Medicine, Tulane University School of Medicine New Orleans, LA ; Department of Tulane Cancer Center New Orleans, LA.
5
Department of Structural and Cellular Biology, Tulane University School of Medicine New Orleans, LA ; Department of Tulane Cancer Center New Orleans, LA ; National Engineering Laboratory for AIDS Vaccine, College of Life Sciences, Jilin University China.

Abstract

Significant advances in our understanding of continued androgen receptor (AR) signaling in castration-resistant prostate cancer have led to the development and FDA approval of two next-generation androgen-directed therapies, abiraterone and enzalutamide. These new therapies heralded a new era of prostate cancer therapy. However, disease progression during androgen-directed therapies remains the most critical challenge in the clinical management of prostate cancer. Accumulating evidence points to an important contribution of constitutively-active AR splice variants to AR-driven tumor progression during androgen-directed therapies. In this review, we will focus on the structure, activity, detection, clinical relevance, and mechanisms of production of AR splice variants.

KEYWORDS:

AR splice variants; Androgen receptor; castration resistance; prostate cancer

PMID:
25374896
PMCID:
PMC4219285

Supplemental Content

Full text links

Icon for PubMed Central
Loading ...
Support Center